BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Ye H, Li T, Wang H, Wu J, Yi C, Shi J, Wang P, Song C, Dai L, Jiang G, Huang Y, Yu Y, Li J. TSPAN1, TMPRSS4, SDR16C5, and CTSE as Novel Panel for Pancreatic Cancer: A Bioinformatics Analysis and Experiments Validation. Front Immunol 2021;12:649551. [PMID: 33815409 DOI: 10.3389/fimmu.2021.649551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu J, Hu G, Gong Y, Yu Q, He B, Li W, He Z, Hao W, He Z, Liu Y. Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer. Pancreatology 2018;18:935-44. [DOI: 10.1016/j.pan.2018.08.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Chiang CC, Yeh CT, Hwang TL, Chu YD, Lim SN, Chen CW, Kuo CJ, Le PH, Chen TH, Lin WR. The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E2225. [PMID: 31888240 DOI: 10.3390/jcm8122225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Song J, Sokoll LJ, Chan DW, Zhang Z. Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays. Biomedicines 2021;9:1897. [DOI: 10.3390/biomedicines9121897] [Reference Citation Analysis]
5 Zhu J, Shu X, Guo X, Liu D, Bao J, Milne RL, Giles GG, Wu C, Du M, White E, Risch HA, Malats N, Duell EJ, Goodman PJ, Li D, Bracci P, Katzke V, Neale RE, Gallinger S, Van Den Eeden SK, Arslan AA, Canzian F, Kooperberg C, Beane Freeman LE, Scelo G, Visvanathan K, Haiman CA, Le Marchand L, Yu H, Petersen GM, Stolzenberg-Solomon R, Klein AP, Cai Q, Long J, Shu XO, Zheng W, Wu L. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev 2020;29:1501-8. [PMID: 32439797 DOI: 10.1158/1055-9965.EPI-20-0091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Burnett-Hartman AN, Udaltsova N, Kushi LH, Neslund-Dudas C, Rahm AK, Pawloski PA, Corley DA, Knerr S, Feigelson HS, Hunter JE, Tabano DC, Epstein MM, Honda SA, Ter-Minassian M, Lynch JA, Lu CY. Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clin Cancer Inform 2019;3:1-10. [PMID: 31487201 DOI: 10.1200/CCI.19.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li M, Wei W, Barnhart TE, Jiang D, Cao T, Fan K, Engle JW, Liu J, Chen W, Cai W. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging 2021;48:2737-48. [PMID: 33537836 DOI: 10.1007/s00259-021-05216-3] [Reference Citation Analysis]
8 Satyananda V, Gupta R, Hari DM, Yeh J, Chen KT. Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed? Gastroenterol Res Pract 2019;2019:7690528. [PMID: 30863442 DOI: 10.1155/2019/7690528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Panebianco C, Pazienza V. Body site-dependent variations of microbiota in pancreatic cancer pathophysiology. Crit Rev Clin Lab Sci 2019;56:260-73. [PMID: 31060399 DOI: 10.1080/10408363.2019.1615407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics 2019;20:113-27. [PMID: 30539680 DOI: 10.2217/pgs-2018-0073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Lee JH, Ahmed O. Endoscopic Management of Pancreatic Cancer. Surgical Oncology Clinics of North America 2019;28:147-59. [DOI: 10.1016/j.soc.2018.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang Y, Jiang T, Jiang M, Gu S. Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis. BMC Cancer 2019;19:177. [PMID: 30808336 DOI: 10.1186/s12885-019-5385-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Patel BN, Olcott E, Jeffrey RB. Extrapancreatic perineural invasion in pancreatic adenocarcinoma. Abdom Radiol (NY) 2018;43:323-31. [PMID: 28980054 DOI: 10.1007/s00261-017-1343-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
14 Zou L, He H, Li Z, Chen O, Jia X, Zhang H. Long noncoding RNA LINC00261 upregulates ITIH5 to impair tumorigenic ability of pancreatic cancer stem cells. Cell Death Discov 2021;7:220. [PMID: 34446696 DOI: 10.1038/s41420-021-00575-0] [Reference Citation Analysis]
15 Sato T, Muramatsu T, Tanabe M, Inazawa J. Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line. Cancer Sci 2018;109:3623-33. [PMID: 30156359 DOI: 10.1111/cas.13783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ali DM, Ansari SS, Zepp M, Knapp-Mohammady M, Berger MR. Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells. Cell Death Discov 2019;5:128. [PMID: 31428460 DOI: 10.1038/s41420-019-0206-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 Zhang Z, Gu J, Yin M, Wang D, Ma C, Du J, Lin Z, Hu S, Wang X, Li Y, Tan G, Luo H, Wei G. Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer. Biomed Res Int 2020;2020:1570862. [PMID: 33015155 DOI: 10.1155/2020/1570862] [Reference Citation Analysis]
18 Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:174-82. [PMID: 30333219 DOI: 10.1158/1055-9965.EPI-18-0483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Chen L, Liu J, Tang T, Zhang YC, Liu MZ, Xu LY, Zhang J. lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma. Onco Targets Ther 2018;11:7955-65. [PMID: 30519037 DOI: 10.2147/OTT.S167065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Xu R, He W, Tang J, Guo W, Zhuang P, Wang C, Fu W, Zhang J. Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression. Experimental Cell Research 2018;363:310-4. [DOI: 10.1016/j.yexcr.2018.01.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
21 Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 2018;19:316-27. [PMID: 29303405 DOI: 10.1080/15384047.2017.1416937] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 11.3] [Reference Citation Analysis]
22 Negoi I, Beuran M, Hostiuc S, El-Hussuna A, de-Madaria E. Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. Hepatobiliary Pancreat Dis Int 2019;18:203-5. [PMID: 31000337 DOI: 10.1016/j.hbpd.2019.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Wu H, Guo JC, Yang SH, Tien YW, Kuo SH. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. J Clin Med 2019;8:E1115. [PMID: 31357636 DOI: 10.3390/jcm8081115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Bouchard DM, Matunis MJ. A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer. J Gastrointest Oncol 2019;10:821-30. [PMID: 31602319 DOI: 10.21037/jgo.2019.05.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med 2021;19:39. [PMID: 33478521 DOI: 10.1186/s12967-021-02701-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Adato O, Orenstein Y, Kopolovic J, Juven-Gershon T, Unger R. Quantitative Analysis of Differential Expression of HOX Genes in Multiple Cancers. Cancers (Basel) 2020;12:E1572. [PMID: 32545894 DOI: 10.3390/cancers12061572] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Michael Traeger M, Rehkaemper J, Ullerich H, Steinestel K, Wardelmann E, Senninger N, Abdallah Dhayat S. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2419-31. [DOI: 10.1007/s00432-018-2755-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Root A, Allen P, Tempst P, Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel) 2018;10:E67. [PMID: 29518918 DOI: 10.3390/cancers10030067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
29 Liang L, Wei DM, Li JJ, Luo DZ, Chen G, Dang YW, Cai XY. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation. Mol Med Rep 2018;17:939-51. [PMID: 29115476 DOI: 10.3892/mmr.2017.7945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
30 Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.Biomedicines. 2020;8. [PMID: 33287196 DOI: 10.3390/biomedicines8120565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Patel BN, Olcott EW, Jeffrey RB. Duodenal invasion by pancreatic adenocarcinoma: MDCT diagnosis of an aggressive imaging phenotype and its clinical implications. Abdom Radiol 2018;43:332-9. [DOI: 10.1007/s00261-017-1271-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Khoshghamat N, Jafari N, Toloue-Pouya V, Azami S, Mirnourbakhsh SH, Khazaei M, Ferns GA, Rajabian M, Avan A. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci 2021;270:119118. [PMID: 33548284 DOI: 10.1016/j.lfs.2021.119118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ferencz S, Reglodi D, Kaszas B, Bardosi A, Toth D, Vekony Z, Vicena V, Karadi O, Kelemen D. PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. Oncol Lett 2019;18:5725-30. [PMID: 31788045 DOI: 10.3892/ol.2019.10971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Liauw SL, Ni L, Wu T, Arif F, Cloutier D, Posner MC, Kozloff M, Kindler HL. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. J Gastrointest Oncol 2020;11:1399-407. [PMID: 33457009 DOI: 10.21037/jgo-20-187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Gao Y, Chen S, Sun J, Su S, Yang D, Xiang L, Meng X. Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: A review. Phytother Res 2021;35:603-28. [PMID: 32965773 DOI: 10.1002/ptr.6847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018;2018:5389820. [PMID: 30186820 DOI: 10.1155/2018/5389820] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
37 Pombeiro I, Loosen SH, Roy S, Schueller F, Niewenhuisen L, Luedde M, Vucur M, Tacke F, Binnebösel M, Schoening W, Trautwein C, Luedde T, Neumann UP, Roderburg C. Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. J Clin Med 2018;7:E175. [PMID: 30011858 DOI: 10.3390/jcm7070175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Zhu J, Yang Y, Kisiel JB, Mahoney DW, Michaud DS, Guo X, Taylor WR, Shu XO, Shu X, Liu D, Li B, Tao R, Cai Q, Zheng W, Long J, Wu L. Integrating Genome and Methylome Data to Identify Candidate DNA Methylation Biomarkers for Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev 2021;30:2079-87. [PMID: 34497089 DOI: 10.1158/1055-9965.EPI-21-0400] [Reference Citation Analysis]
39 Wu Y, Zhou Q, Guo F, Chen M, Tao X, Dong D. S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives. Front Oncol 2021;11:711180. [PMID: 34527585 DOI: 10.3389/fonc.2021.711180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Koerkamp BG, van Eijck CH. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg 2019;270:139-46. [PMID: 29334554 DOI: 10.1097/SLA.0000000000002660] [Cited by in Crossref: 76] [Cited by in F6Publishing: 57] [Article Influence: 38.0] [Reference Citation Analysis]
41 Gowthami J, Gururaj N, Mahalakshmi V, Sathya R, Sabarinath TR, Doss DM. Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review. J Oral Maxillofac Pathol 2020;24:293-307. [PMID: 33456239 DOI: 10.4103/jomfp.JOMFP_348_19] [Reference Citation Analysis]
42 Li XZ, Song J, Sun ZX, Yang YY, Wang H. Diagnostic performance of contrast-enhanced ultrasound for pancreatic neoplasms: A systematic review and meta-analysis. Dig Liver Dis. 2018;50:132-138. [PMID: 29162410 DOI: 10.1016/j.dld.2017.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
43 US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322:438-444. [PMID: 31386141 DOI: 10.1001/jama.2019.10232] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 20.7] [Reference Citation Analysis]
44 Qian L, Li Q, Baryeh K, Qiu W, Li K, Zhang J, Yu Q, Xu D, Liu W, Brand RE, Zhang X, Chen W, Liu G. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res 2019;213:67-89. [PMID: 31442419 DOI: 10.1016/j.trsl.2019.08.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
45 Pekarek L, Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon MA, Acero J, Ruiz-Llorente L, García-Honduvilla N, Albillos A, Buján J, Alvarez-Mon M, Guijarro LG, Ortega MA. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives. Oncol Lett 2021;22:809. [PMID: 34630716 DOI: 10.3892/ol.2021.13070] [Reference Citation Analysis]